127 related articles for article (PubMed ID: 8260243)
1. The prognostic value of nuclear roundness and neopterin in ovarian cancer.
Marth C; Weger A; Müller-Holzner E; Zeimet AG; Moncayo-Naveda H; Daxenbichler G; Reibnegger G; Fuchs D; Wachter H; Dapunt O
Eur J Cancer; 1993; 29A(13):1863-8. PubMed ID: 8260243
[TBL] [Abstract][Full Text] [Related]
2. Clinical significance of neopterin for prognosis and follow-up in ovarian cancer.
Reibnegger G; Hetzel H; Fuchs D; Fuith LC; Hausen A; Werner ER; Wachter H
Cancer Res; 1987 Sep; 47(18):4977-81. PubMed ID: 3621185
[TBL] [Abstract][Full Text] [Related]
3. Long-term significance of urinary neopterin in ovarian cancer: a study by the Austrian Association for Gynecologic Oncology (AGO).
Volgger BM; Windbichler GH; Zeimet AG; Graf AH; Bogner G; Angleitner-Boubenizek L; Rohde M; Denison U; Sliutz G; Fuith LC; Fuchs D; Marth C
Ann Oncol; 2016 Sep; 27(9):1740-6. PubMed ID: 27358381
[TBL] [Abstract][Full Text] [Related]
4. Prognostic value of CA 125 and neopterin in women with ovarian cancer undergoing second-look laparotomy.
Fuith LC; Fuchs D; Reibnegger G; Wachter H
Am J Obstet Gynecol; 1991 Sep; 165(3):779. PubMed ID: 1892210
[No Abstract] [Full Text] [Related]
5. Elevated serum levels of neopterin and soluble interleukin-2 receptor in patients with ovarian cancer.
Gadducci A; Ferdeghini M; Malagnino G; Prontera C; Fanucchi A; Annicchiarico C; Bianchi R; Fioretti P; Facchini V
Gynecol Oncol; 1994 Mar; 52(3):386-91. PubMed ID: 8157196
[TBL] [Abstract][Full Text] [Related]
6. Prognostic value of CD44 splice variant expression in ovarian cancer.
Uhl-Steidl M; Müller-Holzner E; Zeimet AG; Adolf GR; Daxenbichler G; Marth C; Dapunt O
Oncology; 1995; 52(5):400-6. PubMed ID: 7543667
[TBL] [Abstract][Full Text] [Related]
7. Neopterin, a biochemical indicator of cellular immune reactions, in the detection and control of patients with neoplastic diseases.
Hausen A; Bichler A; Fuchs D; Hetzel H; Reibnegger G; Wachter H
Cancer Detect Prev; 1985; 8(1-2):121-8. PubMed ID: 4064032
[TBL] [Abstract][Full Text] [Related]
8. Effects of interferon-alpha on macrophage activation in patients with ovarian carcinoma and cervical dysplasia.
Fuith LC; Fuchs D; Hausen A; Hetzel H; Reibnegger G; Werner ER; Wachter H
J Clin Lab Immunol; 1989 Jun; 29(2):65-9. PubMed ID: 2632803
[TBL] [Abstract][Full Text] [Related]
9. Prognostic relevance of urinary neopterin in non-Hodgkin's lymphomas.
Abate G; Comella P; Marfella A; Santelli G; Nitsch F; Fiore M; Perna M
Cancer; 1989 Feb; 63(3):484-9. PubMed ID: 2912527
[TBL] [Abstract][Full Text] [Related]
10. Urinary neopterin quantification indicates altered cell-mediated immunity in healthy subjects under psychological stress.
Dunbar PR; Hill J; Neale TJ
Aust N Z J Psychiatry; 1993 Sep; 27(3):495-501. PubMed ID: 8250795
[TBL] [Abstract][Full Text] [Related]
11. The prognostic value of morphometry in advanced epithelial ovarian cancers.
Katsoulis M; Lekka J; Vlachonikolis I; Delides GS
Br J Cancer; 1995 Oct; 72(4):958-63. PubMed ID: 7547248
[TBL] [Abstract][Full Text] [Related]
12. Serum neopterin levels in ovarian tumors.
Park IS; Lee YS; Kim JC; Hwang SG
Int J Gynaecol Obstet; 1995 Dec; 51(3):229-34. PubMed ID: 8745088
[TBL] [Abstract][Full Text] [Related]
13. Neopterin as a prognostic indicator in patients with carcinoma of the uterine cervix.
Reibnegger GJ; Bichler AH; Dapunt O; Fuchs DN; Fuith LC; Hausen A; Hetzel HM; Lutz H; Werner ER; Wachter H
Cancer Res; 1986 Feb; 46(2):950-5. PubMed ID: 3940654
[TBL] [Abstract][Full Text] [Related]
14. Differences in pteridine urinary levels in patients with malignant and benign ovarian tumors in comparison with healthy individuals.
Zvarik M; Martinicky D; Hunakova L; Sikurova L
J Photochem Photobiol B; 2015 Dec; 153():191-7. PubMed ID: 26414289
[TBL] [Abstract][Full Text] [Related]
15. Preactivated T cells in cancer patients with poor prognosis.
Fuchs DN; Fuith LC; Hausen A; Hetzel H; Reibnegger GJ; Werner ER; Wachter H
Cancer Detect Prev; 1988; 12(1-6):97-103. PubMed ID: 3141055
[TBL] [Abstract][Full Text] [Related]
16. Urinary neopterin does not reflect the local antitumor immune milieu in ovarian cancer.
Zeimet AG; Reimer D; Schwentner L; Fuchs D; Wolf D; Fuith LC; Fiegl H; Doppler W; Concin N; Daxenbichler G; Marth C
Cancer Immunol Immunother; 2010 Dec; 59(12):1813-23. PubMed ID: 20717669
[TBL] [Abstract][Full Text] [Related]
17. Urinary neopterin in malignant lymphoma.
Piccinini L; Zironi S; Federico M; Pini LA; Luppi G
Int J Biol Markers; 1991; 6(4):231-6. PubMed ID: 1795130
[TBL] [Abstract][Full Text] [Related]
18. Urinary neopterin excretion in patients with uterine sarcomas.
Fuith LC; Fuchs D; Hausen A; Hetzel H; Reibnegger G; Werner ER; Wachter H
Cancer; 1990 Mar; 65(5):1228-31. PubMed ID: 2302670
[TBL] [Abstract][Full Text] [Related]
19. Urinary neopterin reflects clinical activity in patients with rheumatoid arthritis.
Reibnegger G; Egg D; Fuchs D; Günther R; Hausen A; Werner ER; Wachter H
Arthritis Rheum; 1986 Sep; 29(9):1063-70. PubMed ID: 3753537
[TBL] [Abstract][Full Text] [Related]
20. The prognostic value of nuclear morphometric analysis in serous ovarian carcinoma.
Palmer JE; Sant Cassia LJ; Irwin CJ; Morris AG; Rollason TP
Int J Gynecol Cancer; 2008; 18(4):692-701. PubMed ID: 17944918
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
